Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Societal CDMO (SCTL)
NASDAQ:SCTL
Societal CDMO (SCTL) Stock Price & Analysis
380 Followers
SCTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.26 - $1.28
Previous Close$1.09
Volume666.07K
Average Volume (3M)835.81K
Market Cap
$115.07M
Enterprise Value$149.62M
Total Cash (Recent Filing)$8.16M
Total Debt (Recent Filing)$42.70M
Price to Earnings (P/E)-3.7
Beta1.38
Next Earnings
May 08, 2024EPS EstimateN/A
Last Dividend Ex-Date
Nov 22, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding104,788,222
10 Day Avg. Volume1,466,394
30 Day Avg. Volume835,813
Standard Deviation0.37
R-Squared0.05
Alpha-0.00619
Financial Highlights & Ratios
Price to Book (P/B)7.73
Price to Sales (P/S)1.27
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio1246.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.64
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda-32.25
Forecast
1Y Price Target
$1.10Price Target Upside0.92% Upside
Rating ConsensusHold
Number of Analyst Covering4
Societal CDMO News
PremiumCompany Announcements
Societal CDMO Completes Merger and Resolves Financial Obligations
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SCTL FAQ
What was Societal CDMO’s price range in the past 12 months?
Societal CDMO lowest stock price was $0.26 and its highest was $1.28 in the past 12 months.
What is Societal CDMO’s market cap?
Currently, no data Available
When is Societal CDMO’s upcoming earnings report date?
Societal CDMO’s upcoming earnings report date is May 08, 2024 which is in 9 days.
How were Societal CDMO’s earnings last quarter?
Currently, no data Available
Is Societal CDMO overvalued?
According to Wall Street analysts Societal CDMO’s price is currently Undervalued.
Does Societal CDMO pay dividends?
Societal CDMO pays a Notavailable dividend of $1.8 which represents an annual dividend yield of N/A. See more information on Societal CDMO dividends here
What is Societal CDMO’s EPS estimate?
Societal CDMO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Societal CDMO have?
Societal CDMO has 105,572,740 shares outstanding.
What happened to Societal CDMO’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Societal CDMO?
Among the largest hedge funds holding Societal CDMO’s share is Driehaus Capital Management LLC. It holds Societal CDMO’s shares valued at 1M.
---
Societal CDMO Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.10 (0.92% Upside)
$1.10 (0.92% Upside)
Hedge Fund Trend
Increased
By 8.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.92%
12-Months-Change
Fundamentals
Return on Equity
-46.33%
Trailing 12-Months
Asset Growth
0.17%
Trailing 12-Months
Company Description
Societal CDMO
Recro Pharma, Inc. is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.
---
SCTL Earnings Call
Q3 2023
0:00 / 0:00
---
SCTL Stock 12 Months Forecast
Average Price Target
$1.10
▲(0.92% Upside)
Technical Analysis
Avid Bioservices
―
Crinetics Pharmaceuticals
―
Aurinia Pharmaceuticals
―
Medicine Man Technologies
―
Best Analysts Covering SCTL
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+55.45%
reiterated a buy rating 2 months ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +55.45% per trade.
---